Evidence map›Paper›PMID 35197965›Full record

ArticleFrontiers in immunology2021

Increased Fibrosis in a Mouse Model of Anti-Laminin 332 Mucous Membrane Pemphigoid Remains Unaltered by Inhibition of Aldehyde Dehydrogenase.

Sabrina Patzelt, Manuela Pigors, Heiko Steenbock, Leonard Diel, Katharina Boch, Lenche Chakievska, Sven Künzel, Hauke Busch, Anke Fähnrich, Jürgen Brinckmann and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Meeting Report on "10th Anniversary Symposium on Inflammatory Skin Disease".JID innovations : skin science from molecules to population health · 2025
    Article
  6. Review
  7. Autoimmunity against laminin 332.Frontiers in immunology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sabrina PatzeltLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
Manuela PigorsLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
Heiko SteenbockInstitute of Virology and Cell Biology, University of Lübeck, Lübeck, Germany.
Leonard DielLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
Katharina BochDepartment of Dermatology, Allergology and Venerology, University of Lübeck, Lübeck, Germany.
Lenche ChakievskaLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
Sven KünzelMax Planck Institute for Evolutionary Biology, Plön, Germany.
Hauke BuschLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
Anke FähnrichLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
Jürgen BrinckmannInstitute of Virology and Cell Biology, University of Lübeck, Lübeck, Germany.
Enno SchmidtLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
University of Lübeck · DEMax Planck Institute for Evolutionary Biology · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucous membrane pemphigoid (MMP) is an autoimmune blistering disease characterized by autoantibodies against the basal membrane zone of skin and surface-close epithelia and predominant mucosal lesions. The oral cavity and conjunctivae are most frequently affected, albeit clinical manifestations can also occur on the skin. MMP-associated lesions outside the oral cavity typically lead to scarring. Mechanisms underlying scarring are largely unknown in MMP and effective treatment options are limited. Herein, we assessed the collagen architecture in tissue samples of an antibody-transfer mouse model of anti-laminin-332 MMP. In MMP mice, increased collagen fibril density was observed in skin and conjunctival lesions compared to mice injected with normal rabbit IgG. The extracellular matrix of MMP skin samples also showed altered post-translational collagen cross-linking with increased levels of both lysine- and hydroxylysine-derived collagen crosslinks supporting the fibrotic phenotype in experimental MMP compared to control animals. In addition, we evaluated a potential anti-fibrotic therapy in experimental anti-laminin-332 MMP using disulfiram, an inhibitor of the aldehyde dehydrogenase (ALDH), which has been implicated in immune-mediated mucosal scarring. In addition, disulfiram also acts as a copper chelator that was shown to block lysyl oxidase activity, an enzyme involved in formation of collagen crosslinks. Topical use of disulfiram (300 μM in 2% [w/v] methocel) did not improve ocular lesions in experimental MMP over the 12-day treatment period in disulfiram-treated mice compared to vehicle-treated mice (n=8/group). Furthermore, C57BL6/J mice (n=8/group) were treated prophylactically with 200 mg/kg p.o. disulfiram or the solvent once daily over a period of 12 days. Systemic treatment did not show any reduction in the severity of oral and ocular lesions in MMP mice, albeit some improvement in skin lesions was observed in disulfiram- vs. vehicle-treated mice (p=0.052). No reduction in fibrosis was seen, as assessed by immunohistochemistry. Whilst blocking of ALDH failed to significantly ameliorate disease activity, our data provide new insight into fibrotic processes highlighting changes in the collagenous matrix and cross-linking patterns in IgG-mediated MMP.

Indexed as

Autoimmune DiseasesPemphigoid, Benign Mucous MembranePemphigoid, BullousAldehyde DehydrogenaseAnimalsCicatrixCollagenDisease Models, AnimalDisulfiramFibrosisImmunoglobulin GMiceMice, Inbred C57BLMucous MembraneAldehyde DehydrogenaseCollagenDisulfiramImmunoglobulin Galdehyde dehydrogenaseautoimmune blistering diseasecollagencrosslinkingfibrosislaminin 332mouse modelmucous membrane pemphigoid

Identifiers

PMID35197965
PMCPMC8858800
OpenAlexW4210517272

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.